Revolution Medicines’ pan-RAS inhibitor helped patients with a highly aggressive form of pancreatic cancer live an average of six months longer than chemotherapy, hitting a goal of the phase 3 study.

* Total program cost including tuition and required fees ‡ Percent of those seeking jobs who accepted employment within 3 months of graduation Taking advantage of its location in one of North ...

Last July, Pakistan's federal cabinet approved the National AI Policy 2025 with considerable fanfare. The goals were ambitious: a million AI-trained professionals by 2030, AI concepts embedded from ...

A Revolution Medicines drug helped pancreatic cancer patients live nearly six months longer compared to those treated with standard of care chemotherapy, meeting the goals of a pivotal study in this ...

RAS proteins, their regulators and the downstream enzymes that they control are activated in many tumour types by a variety of mechanisms, including oncogenic mutation of RAS genes. They are crucial ...